April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
February 26th 2021
September 12th 2012
August 29th 2012
Prostate cancer survival significantly improved with novel radiation agentAugust 1st 2012
Interim data from a phase III trial of a novel radiation agent in men with castration-resistant prostate cancer (CRPC) showed the agent's efficacy to be significantly sufficient to bring the trial to a halt at a planned interim analysis so as to be able offer the agent to men in the placebo arm.
Companies team up for needle-free botulinum injection platformJuly 11th 2012
American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.
5-alpha-reductase inhibitor use does not compromise PSA utility, study showsJuly 1st 2012
Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.
Investigational agent may boost immune system of kidney Ca patientsJune 27th 2012
Two clinical trials testing experimental drugs aimed at restoring the immune systemâ€™s ability to spot and attack cancer have shown promising early results in patients with kidney cancer, as well as those with advanced non-small cell lung cancer and melanoma.
Janssen submits supplemental applications for prostate cancer therapyJune 27th 2012
Janssen Research & Development, LLC recently submitted a supplemental new drug application to the FDA for abiraterone acetate (ZYTIGA) intended to extend the use of abiraterone administered with prednisone to include the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and before chemotherapy.
More data implicate diabetes agent in increasing bladder cancer riskJune 13th 2012
New data have added to previous evidence that the use of pioglitazone (Actos) appears to be associated with an increased risk of incident bladder cancer among patients with type 2 diabetes, Canadian researchers recently reported.
Adding targeted therapy to hormone therapy may eliminate prostate tumors pre-surgeryJune 6th 2012
Six months of treatment with the targeted androgen biosynthesis inhibitor abiraterone (ZYTIGA), in addition to standard hormonal therapy before prostatectomy, eliminated or nearly eliminated cancer in one-third of men with localized high-risk prostate cancer, a recent study found.
High androgen levels linked with advanced prostate cancer survivalJune 1st 2012
Elevated pretreatment androgen levels correlate with significantly better overall survival in men with castration-resistant prostate cancer, regardless of treatment, a recent post hoc analysis of a large randomized trial showed.
Phosphodiesterase type-5 inhibitors found safe, efficacious for lower urinary tract symptomsJune 1st 2012
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms secondary to BPH, according to a recent systematic review and meta-analysis.
Opinion split on prescribing phosphodiesterase type-5 inhibitors for pleasure onlyJune 1st 2012
Physician opinion is divided almost evenly on the question of whether to prescribe phosphodiesterase type-5 inhibitors to patients for non-medical indications, a survey of Israeli doctors showed.
Multidrug-resistant E. coli common prior to prostate biopsyJune 1st 2012
In men scheduled for transrectal prostate biopsy, 70% of the fluoroquinolone-resistant Escherichia coli isolated from fecal flora represented the epidemic, multidrug-resistant ST131 strain, a recent phylogenic and virulence factor analysis found.
Antimuscarinic decreases nocturnal urgency episodesJune 1st 2012
In treating nocturia related to urgency, flexible-dose fesoterodine (Toviaz) demonstrates statistical superiority to placebo in several areas, according to a study presented at the AUA annual meeting here.
Erectile dysfunction 'drugs' purchased online contain paint, insecticidesJune 1st 2012
Internet-marketed medication purporting to be a generic form of the phosphodiesterase type-5 inhibitor Viagra (sildenafil citrate) is likely to be neither generic nor Viagra but instead is an expertly packaged mix of materials such as paint, insecticides, rat poisons, boric acid, and gypsum, according to a study presented at the AUA annual meeting in Atlanta.
Flexible-dose antimuscarinic decreases nocturnal urgency episodesMay 23rd 2012
In treating nocturia related to urgency, flexible-dose fesoterodine (Toviaz) demonstrates statistical superiority to placebo in several areas, reported researchers from State University of New York Downstate Medical School, Brooklyn.
Internet-marketed PDE-5 inhibitors frequently counterfeit, dangerousMay 23rd 2012
Men who order so-called generic Viagra acquired from the Internet are more likely to be ingesting paint, gypsum, rat poison, and a host of other substances found more often in garages than pharmacies, researchers have discovered.
Phase II data: Investigational OAB agent safe, efficaciousMay 21st 2012
In phase II results presented here yesterday, the investigational beta3-adrenoceptor agonist solabegron yielded statistically significant improvements in symptoms of overactive bladder compared to placebo and was safe and well tolerated, Dutch researchers reported.
Amgen receives complete response letter for denosumab indicationMay 9th 2012
The FDA recently issued a complete response letter for Amgen Inc.'s supplemental Biologics License Application for the RANK ligand inhibitor denosumab (XGEVA) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases.